Clonidine: Phase IIb data

Top-line data from the intent-to-treat (ITT) population (n=180) of a double-blind, U.S. Phase IIb trial showed that thrice-daily ARC-4558 missed the primary endpoint of significantly reducing pain from baseline to week 12 as measured by NPRS vs. placebo (p=0.069). In a prospective subset of 80 patients with at least minimal nociceptor function, ARC-4558 significantly reduced pain vs. placebo (p<0.05) and further in patients with higher levels of nociceptors (n=52; p<0.005). ...